Current methods for evaluating bovine viral diarrhea virus (BVDV) vaccination response typically rely on measurement of humoral responses as determined by virus neutralizing antibody titers (VNT) against BVDV. While VNT are correlated with increased protection, research has also shown that cell mediated immunity (CMI) is an important component of a protective response against BVDV. For example, improved protection against BVDV by modified-live viral (MLV) vaccines as compared to killed vaccines is thought to be due to better CMI induced by the MLV. The goal of this work was to evaluate the cell mediated response in vaccinated calves using a novel PrimeFlow RNA assay that incorporates cell surface marker staining with intracellular RNA expression of cytokines and viral RNA detection. Results from this study evaluating mRNA for IFN-γ and IL-2 at 24 h post-BVDV stimulation are similar to previous studies in which IFN-γ was detected in the CD4+ and CD8+ T cell population. However, a novel observation was the detection of IFN-γ mRNA in the NK cell population in vaccinated animals. The NK cell population contributed a significant portion of the IFN-γ produced. This study also demonstrated a decrease in the frequency and amount of BVDV in PBMCs, harvested from vaccinated calves and exposed to BVDV in vitro. Collectively data from this study highlights the association between an increase in IFN-γ and a decreased infection rate of isolated PBMC's, based on the frequency and amount of BVDV positive cells following in vitro exposure. This new method combines not only the ability to evaluate cellular responses, but also the ability to understand potential antiviral properties associated with cellular responses. This is the first assay to describe and simultaneously measure CMI responses and intracellular viral RNA quantity as a method to evaluate protective responses associated with vaccination.
Introduction
Fetal protection against bovine viral diarrhea virus (BVDV) involves several aspects of the immune response. Serum-neutralizing antibodies are an important component of the immune response and is the most commonly used parameter to evaluate protective responses against BVDV isolates (Alpay and Yeşilbağ, 2015; Neill et al., 2019) . While virus neutralization titers (VNT) are correlated with increased protection against BVDV (Newcomer et al., 2015; Walz et al., 2017) , immune protection can occur in the absence of serum antibodies . Components of the immune response that may contribute to protection not associated with antibodies include mucosal immunity; cytotoxic T cells, which can kill virus infect cells; and T-helper-1 cells, which secrete IFN-γ and have anti-viral properties (Platt et al., 2006; Stevens et al., 2009; Van Anne et al., 2018) . Serum virus-neutralizing antibodies may be sufficient to protect healthy non-stressed animals during an acute infection with BVDV, but conferring fetal protection may require a greater level of protection achieved by effectively stimulating all aspects of acquired immunity including both B and T cell responses (Leyh et al., 2011) . Previous literature has suggested that both modified-live viral (MLV) and killed vaccines containing BVDV exhibit a recall memory response as observed by inducing increased expression of IFN-γ in T-cell subsets after re-stimulation with BVDV (Platt et al., 2006; Stevens et al., 2009; Van Anne et al., 2018) . In addition, MLV vaccines have also been demonstrated to induce an upregulation in CD25 (IL-2 receptor) expression (Platt et al., 2006) . While in T vitro data would support both MLV and killed BVDV vaccines can induce responses associated with protection, conflicting in vivo data supports a benefit to utilizing MLV vaccines as part of a vaccination program (Walz et al., 2017 (Walz et al., , 2018 .
Currently methods to evaluate CMI response involve the antigen stimulation of isolated of PBMC's and direct measurement of secreted cytokines or PCR based detection cytokine mRNA. While both of these methods provide quantification of total secreted or expressed cytokines, these methods do not allow for characterization of response in respective T-cell subsets. Flow cytometry has also been used to simultaneously detect T-cell subsets (CD4 + , CD8 + , and γδ TCR + ), CD25 surface expression, and intracellular IFN-γ protein from the same cells (Platt et al., 2006) , but this method does not allow for detection of intracellular BVDV and did not evaluate the role of NK cells. The majority of NK cells in bovine peripheral blood have been described to be CD3 − CD2 + NKp46 + , characterized as CD335 + in cattle, and are critical to the innate defense against intracellular pathogens (Graham et al., 2009 ). Furthermore, NK cells enhance the adaptive immune response through the early production of T helper (Th)-1 cytokines and interaction with antigen presenting cells (Graham et al., 2009) . Little is known regarding their role in BVDV protective response.
The goal of the current study was to improve flow cytometry methods by incorporating intracellular detection of BVDV. In addition to traditional T cell subsets, NK cells were evaluated for their contribution to CMI in MLV vaccinated calves. The inclusion of NK cells and intracellular BVDV was explored to more accurately characterize the role IFN-γ may contribute to CMI. The assay described in this paper incorporated a new method to detect intracellular BVDV in PBMC subsets (Falkenberg et al., 2017 . While NK cells have been reported to have effector functions associated with acquired immune responses following vaccination (Horowitz et al., 2010) , this population of cells has not been evaluated in response to BVDV. Therefore, intracellular quantitation of BVDV was added to assess the potential antiviral properties associated with increased IFN-γ production. Previous reports have suggested that the addition of exogenous IFN-γ to cell culture monolayers inhibits BVDV replication (Ohmann and Babiuk, 1988) , and fetal protection studies report a reduction in viremia in animals in which increased protection is observed (Walz et al., 2017) . Collectively these results warrant further investigation of in vitro methods to evaluate these observations.
Materials and methods

Animals and sample collection
Five Holstein steers that tested negative for BVDV antigen and antibody were utilized for the study. Three calves were administered commercially available pentavalent MLV vaccines containing BVDV type 1 and type 2, bovine herpes virus-1 (BHV-1), bovine respiratory syncytial virus (BRSV), and parainfluenza type 3 virus (PI-3). Each calf received exclusively only one of the following commercially available vaccines; BoviShield Gold 5, Titanium 5, or Pyramid 5. Three different MLV vaccines were used as pentavalent MLV vaccines differ in their composition with regard to BVDV strains in the vaccines as well as the use of adjuvants as in the Pyramid 5 vaccine. The first dose of each respective vaccine was administered at approximately 4-5 months of age and two revaccinations at approximately 3-4 month intervals between each dose. The commercially available vaccines were used at the recommended volume and per the recommended route of administration. Two negative control calves were administered sterile PBS at the same volume and route as the vaccinated calves. Beginning 10 weeks post last dose of vaccine (3rd vaccination) three sequential sample collections were obtained over the course of a three-week period. The initial sample (sample time point #1) was collected for evaluation of two T cell panels (Table 1) . The second sample collection (sample time point #2) occurred one week later to evaluate the combined T cell panel based on the results from the initial sample collection (Table 1) . Samples obtained for the third sample collection (sample time point #3) were collected one week after the second sample (sample time point #2) and were used to repeat the assay and evaluate inter-assay variability. Furthermore, duplicate samples were obtained at the third collection time point to evaluate intra-assay variability.
The animals used in this study were handled in accordance with the Animal Welfare Act Amendments (7 U.S. Code §2131 to §2156) and all procedures were approved by the Institutional Animal Care and Use Committee of the National Animal Disease Center (ARS-2018-720).
Virus
A noncytopathic (ncp) field isolate (RS886) belonging to BVDV type 2, subgenotype a, was used to stimulate the cultured PBMC's. RS886 was isolated at the NADC (United States) from a clinically normal PI (Liebler-Tenorio et al., 2004) . RS886 has been reported to cause subclinical disease; lymphopenia associated with 40 % decline in lymphocytes from baseline values, and is considered a typical virulence isolate . RS886 was propagated in Madin Darby bovine kidney (MDBK) cells that had been tested and found free of BVDV and HoBi-like viruses as previously described . Cells were grown in complete cell culture medium composed of minimal essential media (MEM; Sigma-Aldrich, St. louis, MO), supplemented with L-glutamine (1.4 mM; Gibco, Life Technologies, Grand Island, NY), 1% of antibiotic-antimycotic-100X (Invitrogen, Life Technologies, Carlsbad, CA), and 10 % FBS(PAA, Ontario, Canada) that was heat inactivated. FBS was tested and found to be free of BVDV and HoBi-like viruses and antibodies against BVDV or HoBi-like viruses. Culture flasks were freeze-thawed and culture medium was centrifuged at 500 × g for 10 min and passed through a 0.45-μm filter to remove any cell debris. Viral titers were determined via dilution on bovine turbinate (BTu) cells (Bauermann et al., 2012) . Endpoints were determined based on immunoperoxidase staining using the monoclonal antibody N2, which binds the E2 protein of the bovine pestivirus used in this study (Bauermann et al., 2013; Ridpath et al., 1994) . Falkenberg, et al. Veterinary Immunology and Immunopathology 221 (2020) 110024 2.3. Isolation and culture of PBMC Blood was collected via jugular venipuncture in tubes containing acid citrate dextrose (ACD). PBMC isolation was accomplished using SepMate tubes according to the manufacturer's instructions (Stemcell Technologies, Cambridge, MA). Briefly, 15 ml density gradient medium (Lymphoprep) was added into each 50 ml SepMate tube through a central hole. Blood diluted 1:2 in sterile PBS was gently poured down the side of the tubes and above a barrier that physically separates Lymphoprep from the blood sample. Tubes were then centrifuged for 10 min at 1,200 × g with the brake on, after which the PBMC layer is poured off into a new 50 ml conical tube and washed with at least 20 mls of PBS. Tubes were centrifuged at 300 × g for 8 min to pellet cells. Residual RBC's were lysed with a hypotonic lyse step accomplished by resuspending the cell pellet in 9 ml of sterile ddH 2 0 for 15 s followed by addition of 1 ml of 10X PBS. Tubes were centrifuged again to pellet cells at 300 × g for 8 min. Cell pellets were resuspended in 5 ml PBS and passed through a 40 μm cell strainer to remove large cell debris. PMBC counts and cell viability for each calf were measured using an automated cell counter from BioRad (TC20). Total live cells were used to adjust cell numbers for each calf, adjusted cell suspensions were centrifuged at 300 × g for 5 min and the cell pellet was resuspended in complete RPMI-1640 supplemented with 10 % (v/v) heat-inactivated FBS (PAA Laboratories Inc. Ontario, Canada), L-Glutamine (ThermoFisher Scientific, Waltham, MA), antibiotic-antimycotic. Two hundred μl of each PBMC suspension containing 10 6 cells were added to respective wells of a 96-well round bottom plate. Cells were plated in triplicate for each respective non-stimulation or stimulation method for each calf. Plated cells were incubated at 37°C in a humid atmosphere of 5% CO 2 for the duration of the stimulation period. After twenty-four hours, 50 μl of media was removed from the respective wells for each calf and replaced with 50 μl of BVDV virus RS886 at an approximate MOI of 1. Forty-eight hours later, 50 μl of media was removed from the respective mitogen stimulated wells and 50 μl of eBiosciences cell stimulation cocktail (PMA/ionomycin; 8 μl diluted in 1 ml complete RPMI-1640) were used as mitogen positive controls. Three wells remained in media only and were used as non-stimulated controls. Two hours after the addition of the mitogen, all plated cells were prepared for use in the flow cytometry assay.
Additional cells were plated from samples collected at sample collection three to assess antiviral effects of exogenous IFN-γ (Kingfisher, INC). For each respective calf, cells were plated in the same manner as described above, consisting of duplicate wells that did not receive IFN-γ and duplicate wells that received 50 μl of IFN-γ at the same time cells were plated. IFN-γ was added at approximately 1 × 10 5 U/mg protein.
Twenty-four hours after plating and the addition of exogenous IFN-γ, BVDV virus RS886 was added as described above.
Monoclonal antibodies and PrimeFlow assay
The list of mAbs, mAb combination for identification of PBMC subpopulations, panel configuration and reagents used are summarized and details can be found in Table 1 . Briefly, the primary mAbs used consisted of; mouse anti-bovine CD3 (Clone MM1A; Isotype IgG1), mouse anti-bovine CD2 (Clone MUC2A, Isotype IgG2a), mouse antibovine, mouse anti-bovine CD4 (Clone IL11A; isotype IgG2a), mouse anti-bovine CD8 (Clone BAQ111A; Isotype IgM), mouse anti-bovine γδ TCR (TCR1-N24, δ chain specific; Clone GB21A, Isotype IgG2b), mouse anti-bovine CD25 (Clone LCTB2A; Isotype IgG3) and CD335 (Clone ASK1; Isotype IgG1). All primary mAbs were purchased from Washington State University (WSU) Monoclonal Antibody Center (Pullman, WA) with the exception of CD335 (BioRad, Hercules, CA). All mAbs were diluted at 1:100 dilution in stain buffer (BD Biosciences, San Jose, CA). Secondary Ab conjugates added wells containing the respective isotypes and consisted of; goat anti-mouse IgM-BUV395 (BD BioSciences, San Diego, CA), Brilliant Violet 711 (BD BioSciences, San Diego, CA), goat anti-mouse IgG1-PE/Cy7 (Southern Biotechnology Associates, Birmingham, AL), goat anti-mouse IgG2a-Brilliant Violet 421 (BioLegend, San Diego, CA), goat anti-mouse IgG2b-Brilliant Violet 711 (BD BioSciences, San Diego, CA) and goat anti-mouse IgG3-BUV395 (BD BioSciences, San Diego, CA).
The sequence of the genomic region coding for N pro -C-E rns (∼1500 nt) of the RS886 virus was provided to the manufacturer to design genespecific oligonucleotide (RNA) target probes. Bos taurus-specific probes for IFN-γ, IL-2, and CD4 were commercially available through the manufacturer. All target probes were designed by Thermo Fisher Scientific, and are considered proprietary by the company.
Preparation of cultured PBMC for flow cytometry
At the end of the culture period, approximately 48 h post-isolation, 24 h post-BVDV stimulation, and 2 h post mitogen stimulation, plates were centrifuged at 300 × g for 2 min. Cells were recovered by aspirating 100 μl of culture medium, which was placed in tubes, and the remaining residual media was decanted by flicking the plate in one swift movement. Triplicate wells for each calf and non-stimulation and stimulation type were resuspended in 50 μl of PBS and then pooled into one well that represented each stimulation or non-stimulation well for each respective calf. The pooled cells were transferred to a 96-well round bottomed plate for further processing. Pooled cell pellets were washed and resuspended twice with PBS, and pelleted by centrifugation at 300 × g for 2 min. After the last wash step, the supernatant was discarded, pellets were resuspended and incubated with 100 μl of the respective primary mAb mix in the dark at room temperature for 15 min for identification of PBMC subpopulations (Table 1) . After two wash steps with PBS, the secondary antibody conjugate mix (100 μl at 1:100 dilution) was added to the respective wells by resuspending the pellet and incubating in the dark at room temperature for 15 min. After two wash steps with PBS, cells were further utilized in the PrimeFlow assay for intracellular BVDV, IFN-γ, and IL-2 detection and quantification as previously described (Falkenberg et al., 2017 .
Flow cytometric analysis was performed using a BD FACSymphony™ A3 flow cytometer (BD Biosciences). Compensation beads from the PrimeFlow kit as well as CompBeads (BD BioSciences, San Diego, CA) were used to set up compensation for each fluorochrome. While positive signals were evident, single stain controls and fluorescence-minusone controls were evaluated to optimize acquisition gates and compensation for each fluorochrome/channel. Both Alexa Fluor (AF) 647 and AF750 were excited using a red laser (637 nm) and emission signals were collected with 670/30 nm and 780/60 nm band-pass detection filter, respectively. PE/Cy7 and AF568 were excited using a yellow/ green laser (561 nm) and emission signals were collected with 780/60 nm and 610/20 nm band-pass detection filter, respectively. AF488 was excited using the blue laser (488 nm) and emission signal was collected with 515/20 nm band-pass filter. BV711 and BV421 were excited using a violet laser (408 nm) and emission signals were collected with 450/50 nm and 710/50 nm band-pass detection filter, respectively. BUV395 was excited using the UV laser (355 nm) and emission signal was collected with 379/28 nm band-pass filter. Cells were visualized in forward and side light scatter and electronic gates were placed on the scatter region that contained live cells. Doublet discrimination was then used to analyze single cells. At least 50,000 events were collected for each sample for data analysis.
Mitogen (PMA/ionomycin) stimulated and non-stimulated controls were included in each analysis as positive and negative controls, respectively, to assess IFN-γ and IL-2 expression in total PBMCs ( Table 2) . The mitogen and non-stimulated PBMCs were included to; validate the functionality and optimize acquisition gates to detect the presence of IFN-γ and IL-2 in cultured PBMCs and control for background.
Immunofluorescence microscopy
Remaining cells in the wells following flow cytometry, were subjected to IF microscopy to visualize flow cytometry results. Fifty μl of the remaining cell suspension was spun onto glass slides using a Cytospin cytocentrifuge (Thermo Shandon Cytospin 3) at 10.16 × g for 3 min and coverslips were mounted using ProLong Gold antifade mount medium with DAPI (ThermoFisher, Carlsbad, CA). Fluorescent imaging was performed on a Nikon A1R + Confocal System microscope (Nikon Instruments, Melville, NY), using two fluorescent channels (AF488 and AF647) using a 40 X oil-immersion objective. NIS-Elements Advanced Research software was used for image analysis and metadata files were saved as proprietary Nikon ND files.
Serology
Blood was collected to harvest serum prior to vaccination and approximately 10 weeks post last booster vaccination for evaluation of titer response to vaccination for BVDV. Blood was collected into serum separation tubes with gel and clot activator (BD Vacutainer SST, Franklin Lakes, NJ), centrifuged (25 min at 1200 × g), serum collected and frozen at −80°C until processing. A comparative VNT was determined using cytopathic isolates BVDV-1a-Singer and BVDV-2a-296c as previously described . Briefly, serum was diluted in MEM from 1:2 to 1:65,536 in 96 wells plates, and 200 TCID 50 of virus was added to each well. After a 1 h incubation at 37°C with 5% CO 2, 2 × 10 5 BTu cells were added to each well. After four days of incubation, dilution endpoints were determined by observing cytopathic effect (CPE) in cell monolayer. Results were expressed as the reciprocal (Log2 base) of the highest serum dilution able to inhibit the appearance of CPE in cells. Samples with antibody titers equal of higher than 1:4 were considered positive. Serum samples were run in a 96 well plate with five wells per dilution and titers were calculated by the Reed-Muench method.
Data analysis
The frequency of cells staining positive for the respective PBMC populations (CD2 + , CD3 + , CD4 + , CD8 + , γδ + , and CD335 + ) was calculated for each sample. For data from the first sample collection, the percent of positive cells for IFN-γ and IL-2 was determined for each cell population evaluated. For data from the second and third sample collection, within each cell population evaluated, the percent of positive cells for CD25, BVDV, IFN-γ, and IL-2 was determined. The percent positive cells for IFN-γ and IL-2 was determined by subtracting the background expression in the non-stimulated cells from the BVDV stimulated cells. The geometric mean fluorescent intensity (gMFI) was determined for the BVDV positive cells for samples from the second and third sample collection. The data from the second and third sample collection was initially analyzed to determine the effect of inter-assay and intra-assay variability using a model that included the effect of replicate over time and within day, determined by PROC GLM using the SAS system of windows SAS Inst. Inc., Cary, NC). No inter-or intraassay effects were observed (P > 0.1). The duplicate data from the third sample collection was averaged. Averaged data from the third sample collection was combined with data from the second sample collection and results are presented as means for the combined data. Significance of differences were determined by PROC GLM using the SAS system of windows SAS Inst. Inc., Cary, NC). The model included the fixed effect of treatment (Vaccinated and Non-vaccinated) for variables of interest. Least squares means contrasts between vaccinated and non-vaccinated calves were determined using predicted differences, and only when the differences were statistically different (P < 0.01) means were compared.
Results
Serological and mitogen response
All calves were seronegative to BVDV types 1 and 2 prior to vaccination. The non-vaccinated calves remained seronegative throughout the study. Vaccinated calves seroconverted as evidenced by detection of neutralizing antibodies. In vaccinated calves, VNT for BVDV2 ranged from 128 to 2048 and titers for BVDV1 ranged from 128 to 512.
The response to the mitogen stimulation was similar among all calves for IFN-γ and IL-2, regardless of vaccination status (Table 2) , indicating cells were functional after 48 h in culture. Furthermore, minimal background expression was observed for all calves for IFN-γ and IL-2 in the non-stimulated PBMCs, regardless of vaccination status (Table 2) , indicating a lack of exogenous stimulus in the culture system. To further characterize T cell responses to BVDV, two T cell panels were evaluated for T cell subsets that had the greatest expression of IFN-γ and IL-2 in vaccinated calves compared to non-vaccinates. Two panels were initially evaluated due to the multiple antibody clones with the same isotype and the inability to evaluate in the same panel. The T cell subsets identified in each respective panel that had the greatest expression in vaccinates were chosen to comprise the final panel.
Evaluation of two T cell subset panels
Both CD4 + surface expression, as determined by mAb binding, and mRNA expression, as determined by the PrimeFlow CD4 probe, were determined in panel 1. Total CD4 + cells as defined by surface expression for all calves was 36.3 percent as compared to 34.7 percent as detected by the CD4 PrimeFlow mRNA probe (Table 3) . Negligible differences were observed when using surface expression versus mRNA expression to define the CD4 + population as both methods labeled the same population of cells regardless of message or protein expression to define the population. This provided the opportunity to evaluate T cell subpopulations using the PrimeFlow specific probes, and the flexibility to incorporate T cell specific subpopulations of interest into one panel rather than two panels due to isotype duplication in the panel. Both mAb clones for CD4 and CD2 are IgG2a and for this reason cannot be used in the same panel unless one of the clones is directly conjugated or PrimeFlow probes are designed for the marker of interest. One limitation is the lack of directly conjugated fluorochrome options with respective to cattle specific mAbs and for this reason the PrimeFlow probes were selected to use for CD4 + population. IL-2 expression was observed in the mitogen stimulated cells for both vaccinated and non-vaccinated calves ( Table 2) . Twenty-four hours after stimulation with BVDV, regardless of vaccination status, minimal IL-2 expression was observed for the total PBMCs for all calves. Similar expression was observed between the BVDV sand non-stimulated cells ( Table 2 ). The lack of IL-2 expression in response to 24 -h BVDV stimulation was observed in all specific T cell subsets (data not Falkenberg, et al. Veterinary Immunology and Immunopathology 221 (2020) 110024 shown).
In general, a trend in the increase in IFN-γ was observed in total PBMCs from vaccinated calves as compared to non-stimulated controls and non-vaccinated calves ( Table 2 ). In regard to the specific cell subsets, when stimulated with BVDV, a trend in an increased in IFN-γ was observed for the CD2 + , CD3 + , CD4 + , CD8 + , and CD335 + , but minimal to no increase was observed in the γδ-T cell population (Table 3 ). Based on the initial comparisons of the two flow cytometry panels, CD4 + , CD8 + , and CD335 + had the greatest expression of IFN-γ (Table 3 ). CD2 is expressed on all subsets of interest, CD4 + , CD8 + and CD335 + cells, for this reason CD2 was included as a general T cell and natural killer (NK) cell marker. Given the low expression of IFN-γ (Table 3) and IL-2 (data not shown) in the γδ population, the γδ T cell marker and the CD3 marker (also expressed on γδ T cells) were excluded from the final panel.
T cell subset comparisons between vaccinated and non-vaccinated calves
IFN-γ and IL-2 expression in the T cell subsets of interest were evaluated in addition to the surface expression of CD25 and the frequency and gMFI of BVDV positive cells. Mean contrasts between vaccinated and non-vaccinated calves were determined. Similar to the initial panel comparisons, no differences were observed in IL-2 expression between vaccinates and non-vaccinates. Statistically significant differences (P < 0.01) were observed for increased expression of CD25 in vaccinates as compared to non-vaccinates in the CD2 + and CD4 + T cell subsets (Table 4 ). No statistically significant differences (P > 0.05) were observed in the CD8 + and CD335 + T cell subsets. The difference observed in the CD2 + subset is most likely a result of the increased expression in the CD4 + subset. An approximate two-fold increase in CD25 expression was observed in the vaccinated calves (18.05 %) as compared to the non-vaccinated (9.8 %) calves in the CD4 + subset. Fig. 1 depicts the variability within treatment groups over multiple time points for CD25 expression in the CD2 + (Fig. 1A) and CD4 + (Fig. 1B) subsets. The greatest variability was observed in the non-vaccinated calves, for the CD2 + subset, which could be due to the lack of CD25 expression difference in the CD8 + and CD335 + populations between the non-and vaccinated calves. While there was little variability in CD25 expression within the CD4 + subset in both the non-vaccinated calves, the increased CD25 expression would support a specific antigen recall response in the vaccinated calves. Statistically significant differences (P < 0.01) were observed for increased expression of IFN-γ in vaccinates as compared to non-vaccinates in the CD2 + , CD4 + , CD8 + , and CD335 + T cell subsets (Table 4) . Approximately 18 % of the CD335 + cells stimulated with BVDV were positive for expression of IFN-γ, followed by 3.27 % of the CD4 + , 2.85 % of the CD8 + and 2.68 % of the CD2 + in vaccinated animals (Table 4 ). Only 1.73 % of the CD335 + cells were positive for expression of IFN-γ, less than 0.25 % of the CD2 + , CD4 + and CD8 + cells were positive in the non-vaccinated calves (Table 4 ). Furthermore, Fig. 2 
Table 3
Frequency of interferon-γ (IFN-γ) producing cells after stimulation with BVDV for each respective T cell subset. Values in parenthesis indicate the T cell subset specific positive cells as a percent of total PBMCs. Falkenberg, et al. Veterinary Immunology and Immunopathology 221 (2020) 110024 illustrates the variability within treatment groups over multiple time points for IFN-γ expression in the specific T-cell subsets. The greatest variability was observed in the vaccinated calves, which could be expected due to different responses to vaccination and the recall response.
More so, the lack of variability in the non-vaccinated calves suggests minimal background stimulation and indicates a specific antigen recall response in the vaccinated calves for the T cell subsets evaluated. While no differences (P < 0.05) were observed for the frequency of BVDV positive cells in vaccinates as compared to non-vaccinates in the T cell subsets evaluated (Table 4) , there was a general trend in less BVDV positive cells in the CD2 + , CD4 + , and CD8 + T cell subsets. A trend toward increase in the number of BVDV positive cells was observed for the CD335 + cells. Approximately a 10 % decrease in the frequency of BVDV positive CD2 + , CD4 + and CD8 + was observed in the vaccinated calves as compared to the non-vaccinated calves, whereas an approximate 40 % increase in the frequency of BVDV positive CD335 + was observed in the vaccinated calves as compared to the non-vaccinates. In addition to decreased frequency of BVDV positive cells, a decrease in the gMFI was also observed in all cell subsets evaluated for the vaccinated calves as compared to the non-vaccinates. Collectively the decrease in the frequency of BVDV positive cells in combination with a decrease in the gMFI would suggest less amounts of BVDV was observed in the cells of the vaccinated calves. Retrospectively, to better quantify intracellular BVDV, an intracellular BVDV infection index was calculated, by multiplying the frequency of BVDV positive cells by the BVDV gMFI. When comparing differences between vaccinates and non-vaccinates using the intracellular BVDV infection index, differences were approaching significance (P < 0.05) in the CD2 + and CD4 + subsets. To further elucidate these findings, exogenous IFN-γ was added to additional wells 24 h prior to adding BVDV and this resulted in greater than a 50 % reduction in the frequency of BVDV positive cells in addition to a decrease in the gMFI in the IFN-γ treated wells (data not shown). Using the same intracellular BVDV infection index calculation, differences (P < 0.01) were observed between the IFN-γ treated and non-treated wells.
Immunofluorescence microscopy (IF)
IF microscopy was used to visually corroborate the flow cytometry results. In addition to detecting the presence of BVDV, IF microscopy was used to compare the amount of virus incorporated in the cells of vaccinated and non-vaccinated calves (Fig. 3 ) Images obtained for IF microscopy corroborated the gMFI flow cytometry results. The red fluorescent signal in the PBMCs from vaccinated calves was unremarkable and only small punctate areas of staining could be visualized ( Fig. 3B and D) . The amount of red fluorescent signal associated with BVDV labeling was more substantial in the PBMCs from nonvaccinated calves (Fig. 3A and C) . Additionally, while there are a greater number of cells red stained cells, there is also a greater amount of red virus associated staining. This can be appreciated by the more significant red punctate staining in the PBMCs from the non-vaccinated calves (Fig. 3C ) as compared to the vaccinated calves ( Fig. 3D ). No fluorescence signal was detected in non-BVDV stimulated (negative control) PBMCs.
Discussion
Previous research has indicated an association between the quantity of BVDV in blood and clinical outcome. Cows that give birth to PI animals have prolonged or increased viremia (Walz et al., 2018) . The degree of viremia induced during BVDV infection is associated with variations in severity of clinical disease as defined by increased number of days of pyrexia and decrease in circulating lymphocytes (Walz et al., 2001) . PI calf health outcomes are associated with the frequency of BVDV positive PBMC populations . Collectively, this research suggests that the frequency of BVDV positive cells and the amount of BVDV in blood is an important indicator of clinical outcomes associated with BVDV infections and should be considered for immunological assays. However, reliable and consistent methods for intracellular staining of BVDV by flow cytometry have been problematic (Qvist et al., 1990 (Qvist et al., , 1991 . Only recently a new flow cytometry method was developed that reliably and reproducibly detects and quantifies the number of BVDV positive cells within respective cell populations at the single cell level (Falkenberg et al., 2017 . This new method of BVDV intracellular detection was further expanded to incorporate cell responses previously reported to be associated with CMI in the development of a new assay.
Previous research has demonstrated cattle vaccinated with MLV vaccines containing BVDV exhibit a recall memory response as observed by inducing an up regulation in CD25 (IL-2 receptor) and increased intracellular IFN-γ protein in T-cell subsets after re-stimulation with BVDV (Platt et al., 2006) . The drawback with this procedure and incorporating intracellular BVDV detection is the timing of intracellular IFN-γ protein accumulation was observed up to 4 days after stimulation. While it takes up to 4 days to observe IFN-γ protein, differences in the frequency of intracellular BVDV infection are observed within the first 24−48 h after inoculation and are less remarkable by day 4. Therefore, the 24−48 h window after BVDV stimulation was a critical time point to target for analysis and to incorporate cell mediated responses and BVDV positive cells. Previous research has suggested that upregulation in cytokine gene expression in PBMCs occurs within the first 24 h of BVDV stimulation (Lee et al., 2008) . The PrimeFlow RNA assay allows for detection of mRNA for IFN-γ and IL-2 rather than needing to allow long-term cultures for IFN-γ and IL-2 intracellular protein accumulation, therefore decreasing the time after BVDV stimulation that IFN-γ and IL-2 mRNA could be detected. Prior to initial evaluation of the panel, a time course was conducted (data not shown) to determine the optimal time point that would allow simultaneous detection of IFN-γ and IL-2 mRNA expression as well as discern differences in amount of intracellular BVDV. While greater than 24 h was a more optimal time point for intracellular BVDV differences, the expression of IFN-γ and IL-2 mRNA was insignificant at this time. For this reason, the 24 -h time point was utilized for development of this new assay.
Calves utilized for development of the current assay were vaccinated three times with approximately 3-4 months between revaccination. Previous publications have indicated that vaccination in the face of antibody blocks humoral responses, but not T cell responses . For this reason, calves were vaccinated multiple times to ensure calves responded to vaccination. The increase in the presence of IFN-γ mRNA detected 24 -hs after BVDV stimulation in vaccinated Fig. 3 . Immunofluorescent microscopic detection of BVDV RNA (red color) using RNA PrimeFlow Assay. Representative confocal microscopy images for cells from; (A and C) non-vaccinated calves, (B and D) vaccinated calves showing BVDV RNA differences between different vaccination statuses, with a greater number of BVDV positive cells and a cells with a greater amount of BVDV from non-vaccinated calves. All cell lines were processed as described in the materials and methods section. calves in this study, is consistent with previously published observations of an increase in intracellular IFN-γ protein and CD25 expression in the CD4 + and CD8 + T cells after stimulation (Platt et al., 2006) . While previous assays have used detection of IFN-γ intracellular protein, it would be expected that IFN-γ mRNA expression would be detectable prior to detection of IFN-γ intracellular protein. Furthermore, CD25 expression was detected at 24-hs in the CD2 + and CD4 + T cells populations as well as previous reports of upregulation in CD25 approximately 4 days after BVDV stimulation. While other reports have suggested an increase in intracellular IFN-γ protein in the γδ T cell population, no increase was detected for IFN-γ mRNA at 24 -hs post BVDV stimulation in the current assay. While NK cells have been described to secrete IFN-γ, previous cell mediated assays for BVDV have not defined the role of these cells in CMI. Results from the current study suggest over 15 % of the NK cells from vaccinated calves express IFN-γ mRNA 24 -hs after BVDV stimulation. This is the first report of these findings in the literature. Although NK cells are considered innate cells, these findings would suggest immune training or an antigen specific response in the NK cell population after stimulation with BVDV in vaccinated calves. Alternatively, NK cell IFN-γ production may be secondary to antigen specific responses and cytokine expression by T cell subsets in culture. This is an important finding as the NK cell population only comprises a small percent of the total PBMC population, but can significantly contribute to rapid production of IFN-γ.
IFN-γ has been demonstrated to have antiviral properties as previously reported (Ohmann and Babiuk, 1988) , and results from the current study would corroborate these findings. While not significant (P > 0.05), the frequency and gMFI of BVDV positive cells was less in vaccinated calves as compared to non-vaccinates. Furthermore, when exogenous IFN-γ was added to PBMCs 24 -hs prior to the addition of BVDV for stimulation, a substantial decrease in the frequency and gMFI of BVDV positive cells was observed. Multiple dilutions/concentrations of IFN-γ was added to cultured PBMCs, and no effect of concentration was observed (data not shown), suggesting that even small amounts of IFN-γ can exhibit antiviral properties. In the case of adding exogenous IFN-γ, PBMCs could have potentially 48 h total of IFN-γ exposure as compared to less than 24 h after the adding BVDV in the case of the cell mediated assay. While 48 h after BVDV stimulation would have been more optimal to evaluate BVDV positive cells in the vaccinated and non-vaccinated calves, as previously discussed, this was not ideal for evaluation of mRNA for IFN-γ and IL-2. For this reason, concessions were made to incorporate a time point that both BVDV and mRNA for IFN-γ and IL-2 could be measured and evaluated for differences between vaccinated and non-vaccinated calves.
These collective results would suggest that the newly developed assay provides the opportunity to incorporate not only a new cell population for evaluation of cell mediated responses, but also incorporates the ability to quantify and quantitate BVDV positive cells in the context of immunological responses in vaccinated animals. This is a significant finding and the first example of this to be reported. Furthermore, individually, the expression of IFN-γ in the respective cell populations, and the frequency of BVDV positive cells is important; but together these data may provide further insight into understanding the interaction of these two findings. To incorporate implications of the association between the increase in IFN-γ and the decrease in BVDV positive cells, a ratio of the two (IFN-γ:BVDV) should be explored as a method to quantitate the cellular response to BVDV. This approach is currently being evaluated in our lab.
New methods are needed to better characterize protective responses associated with vaccination. VNT has been the gold standard to evaluate response to BVDV vaccination, but this method only allows for evaluation of humoral immunity. To more effectively describe protective responses, both humoral and cell mediated responses need to be considered for a holistic approach to protection. The differences in antibody decay and cell mediated response over time may vary and a better understanding is needed to compare humoral and CMI over time.
Furthermore, new methods are needed to better evaluate responses to different vaccination programs or approaches and to current and newly developed BVDV vaccines, rather than just relying on one component of the immune system (VNT) to determine levels of protection. Further studies will be conducted to determine if this novel assay can be used to compare CMT cross reactivity among BVDV isolates. Quantification of humoral and CMT cross reactivity will allow for better and cheaper evaluation of the level/breadth of cross protection afforded by vaccines.
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